Clinical trial Recruiting at 4 sites Interventional Ages 21 to 65 Women only

Comparing different acellular dermal matrices for breast reconstruction

Official title: The BREAST Trial: A Randomized, Non-inferiority, Study Comparing the Complication Profile of Four Commercially Available Acellular Dermal Matrixes Used in Alloplastic Breast Reconstruction

Run by University of British Columbia · NCT04661501 · Data updated 2026-11-12

This study is testing which of four different materials used in breast reconstruction helps prevent fluid buildup after surgery in women undergoing this procedure.

Quick facts

Study typeInterventional
Ages21 Years to 65 Years
SexWomen only
Enrollment328 (estimated)
SponsorUniversity of British Columbia
Academic / other
Drugs / interventionsradiation
Locations4 sites (Vancouver, British Columbia and 3 other locations)
StatusRecruiting
StartedNovember 25, 2020
Main results expectedDecember 31, 2025
Study endsDecember 31, 2025
Registry record updatedDecember 16, 2024
Trial IDNCT04661501 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women aged 21 to 65 undergoing unilateral or bilateral mastectomy with plans for alloplastic breast reconstruction using ADM.

Probably not a fit

Patients undergoing autologous reconstruction or those with contraindications to the ADMs will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is a randomized single-blinded prospective study that evaluates the surgical outcomes of four different acellular dermal matrices (ADMs) used in alloplastic breast reconstruction. Participants will be randomly assigned to receive one of the four ADMs: AlloDerm, AlloMax, DermACELL, or Flex HD, during a two-stage reconstruction process involving tissue expanders. The primary focus is to compare the incidence of clinically significant post-operative seromas requiring intervention over a two-year follow-up period. The trial will begin with a pilot phase targeting 40 patients to assess feasibility and establish necessary protocols.

Why it matters

Potential benefit: If successful, this study could help identify the most effective ADM for breast reconstruction, potentially reducing complications and improving patient outcomes.

How similar studies have gone: While this approach is being tested in this specific context, previous studies have shown varying outcomes with different ADMs, indicating that this comparison could provide valuable insights.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* All woman aged 21 years or older but less that 65 undergoing unilateral or bilateral mastectomy with alloplastic breast reconstruction using ADM.
* Breast reconstruction must be done by means of a two staged process using tissue expanders and ADM based reconstruction followed by implant tissue expander to implant exchange.

Exclusion Criteria:

* Patients undergoing autologous reconstruction either at the time of mastectomy or in a delayed fashion.
* Patients with a history of previous breast reconstruction procedures.
* Patients with prior radiation treatment to the breast or with prior mantle radiation
* Any patient with a contraindication to breast reconstruction
* Patients undergoing an axillary node dissection with clearance
* Patients with an allergy to Polysporin or any of its ingredients.
* Patients with contraindications to any of the acellular dermal matrices:

  • DermACELL: Allergy to Gentamicin, Vancomycin\[12\]
* The surgeon performing the breast reconstruction may also deem a patient ineligible if intraoperatively, there is evidence of significant mastectomy flap ischemia prior to the initiation of the breast reconstruction procedure.

Where it's running

  • Mount Saint Joseph's Hospital
    Vancouver, British Columbia, Canada
    Recruiting
  • Vancouver General Hospital
    Vancouver, British Columbia, Canada
    Recruiting
  • UBC Hospital
    Vancouver, British Columbia, Canada
    Recruiting
  • Saint Paul's Hospital
    Vancouver, British Columbia, Canada
    Recruiting

Study contacts

  • Principal investigator: Dr. Nancy Van Laeken — University of British Columbia
  • Study coordinator: Dr. Nancy Van Laeken
  • Email: nancy@vanlaeken.com
  • Phone: 604-669-1633

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.